Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

PARTNER 1 in +90 Year Old Patients: TAVI and the Age Paradox

A new analyzis of the PARTNER 1 trial showed that patients over 90 undergoing transcatheter aortic valve replacement (TAVI) show no increase in mortality or major cardiovascular events rates, compared to younger patients.

In fact, patients over 90 undergoing TAVI have the same life expectation of someone the same age with no aortic stenosis.

In-hospital outcomes were similar to those of younger patients, though the 90 year olds often required a longer hospital stay.

Mortality at 30 days and stroke also resulted equivalent between 90 year olds and younger patients, major bleeding being the only disadvantage for the eldest patients (+90 years 11%, 80-90 years 9.8% and -80 years 6.9%; p=0.04), though this difference disappeared when adjusting by baseline characteristics. Echocardiography end points did not favor patients over 90, since they showed a higher prevalence of paravalvular leak, both at discharge and at one year.

More articles by this author

PARTNER 2A: TAVI Not Inferior to Surgery in Intermediate Risk Patients

Transcatheter aortic valve replacement (TAVI) with the new generation balloon expandable valve is at least as good as surgery in intermediate risk patients with...

The SAPIEN 3 Valve Resulted Superior to Surgery in an Observational Study

The last generation of the balloon expandable valve resulted superior to surgery in intermediate riskpatients, in a registry analyzis. Patients treated with the SAPIEN...

CoreValve US Pivotal: at 3 Years, the Self-Expanding Valve Maintains Its Advantage vs. Surgery

At 3 year follow up, the CoreValve US Pivotal study on high risk elderly patients, the self-expanding valve showed a lasting benefit vs. surgery. These...

DANAMI 3: Deferred Stenting and Ischemic Postconditioning Have No Benefit in Primary PCI

Both ischemic postconditioning and deferred stenting showed no benefit in randomized studies conducted as part of the DANAMI 3 program. Both the DANAMI 3-DEFER and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...

DOUBLE-CHOICE: Lower Pacemaker Implantation Rates with ACURATE neo2 Compared with Evolut in Patients Undergoing TAVI

The DOUBLE-CHOICE trial is a multicenter, randomized, controlled study conducted in Germany to evaluate the performance of next-generation transcatheter heart valves and different anesthesia...

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...